"CAIN457A3404-REALIAA non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment patterns of SecukInumab and current standard of care inpatient with chronic plaque psoriAsis eligible for systemic treatment in the Asia-Pacific and Middle East regions" |
Ongoing |
Cosyntex |
4 |
IN457A3404 |
King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patIeNts with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a |
Ongoing |
Interferon Beta-1 a (Rebif) |
4 |
MS200136_0 |
King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah) |
Real World retrospective study of effectiveness and safety of Gilenya (FINgOlimod) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA) |
Ongoing |
Fingolimod |
4 |
TY720DAE01 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah), King Abdulaziz Hospital Oncology Center, King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), Hira Hospital (Makkah), King Fahad Specialist Hospital (Dammam), Dr. Erfan & Bagedo General Hospital (Jeddah) |
Does the Addition of Proton Pump Inhibitors to Continuous Enteral Feeding Provide Added Protection Against Upper GI Bleeding in Acutely Ill Patients |
Ongoing |
Esmoprozol |
4 |
RC15/079 |
King Abdulaziz Medical City NG (Riyadh) |
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease |
Ongoing |
ombitasvir \ paritaprevir \ ritonavir |
3 |
Version 1.3.1 |
King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah) |
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis |
Ongoing |
ofatumumab |
3 |
COMB157G2301 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan |
Terminated |
Lixisenatide |
3 |
LPS14410 |
King Khalid University Hospital (Riyadh) |
"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation" |
Ongoing |
deferasirox |
2 |
CICL670FIC05 |
King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh) |
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease. |
Ongoing |
Sevuparin |
2 |
TVOC01 |
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), Qatif Central Hospital |
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant |
Ongoing |
palbociclib fulvestrant |
3 |
ICRG 1201 |
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah) |